by Okapit | Jul 18, 2024 | Uncategorized
Rokote Laboratories Finland Oy is starting the first clinical drug trial with its nasal COVID-19 vaccine. The vaccine has been developed and manufactured in Finland, and the study will be conducted at Kuopio University Hospital starting January 21, 2025. The...
by Okapit | Dec 9, 2023 | Uncategorized
Finnish vaccine development company Rokote Laboratories Finland Oy is pleased to announce the appointment of its Research and Development Director, Erkko Ylösmäki, as the new CEO, effective January 1, 2024. The company plans to initiate clinical trials for its vaccine...
by Okapit | Oct 27, 2023 | Uncategorized
The European Society of Gene and Cell Therapy (ESGCT) board honors Professor Seppo Ylä-Herttuala for his exceptional career achievements and has selected him as the winner of the 2023 ESGCT Outstanding Achievement Award. The award is the most prestigious award...
by Okapit | Sep 22, 2023 | Uncategorized
Our CEO, Tuija Keinonen, will give a presentation titled ‘Rokote Approach for Nasal Vaccination’ at the World Vaccine Congress Europe in Barcelona on Tuesday, October 17th, at 12:05 PM. We are delighted to have this opportunity to discuss intranasal...
by Okapit | Sep 18, 2023 | Uncategorized
Following the completion of the research and development phase for Rokote Laboratories Finland Oy’s FINCoVac 2.1 coronavirus vaccine in early summer, the vaccine has advanced to the next stage in the production process at a designated contract manufacturer. This...
by Okapit | Apr 5, 2023 | Uncategorized
Rokote Laboratories Finland Oy is developing a coronavirus vaccine and the clinical trials should start during 2023. The development of the company’s FINCoVac vaccine has been rapid as it is based on knowledge gained from long-term research. Despite this, the journey...
